If licensed, the drug can provide people who are not protected by a vaccine with another defense against the disease
According to clinical trial results announced on Monday, a monoclonal antibody mixture developed by drug manufacturer Regeneron provides strong protection against Covid-19 when living with people with coronavirus infection. If licensed, the drug can provide people who are not protected by a vaccine with another defense against the disease.
These findings are the latest evidence. These laboratory-made drugs can not only prevent the worst disease results when used as early as possible, but also help people avoid illness from the beginning.
There is no need to use cumbersome drugs on a large scale: vaccines are sufficient for the vast majority of people and are becoming more and more accessible.
Nevertheless, antibody drugs like Regeneron can still provide doctors with a new way to protect high-risk groups who have not yet been vaccinated or who have not responded well to vaccination, such as taking drugs that weaken immunity. This may be an important tool because the increase in coronavirus cases and the threat of dangerous virus variants will overrun the vaccine.
Regeneron said that he will ask the Food and Drug Administration to expand the scope of emergency authorization for the drug. At present, the drug is suitable for high-risk people who have already suffered from Covid but have not yet been hospitalized, so that the drug can be used preventively in “appropriate people”.
Regeneron’s cocktail is a mixture of two drugs designed to mimic the antibodies that the immune system naturally produces when defending against viruses. Last fall, when President Donald J. Trump was put under management after falling ill with Covid, it received a lot of publicity.